Active Ingredient History
Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Tadalafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with tadalafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, tadalafil should not cause an erection.Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP. Tadalafil is used for the treatment of erectile dysfunction. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abdominal Neoplasms (Phase 1)
Altitude Sickness (Phase 1/Phase 2)
Andropause (Phase 4)
Anemia, Sickle Cell (Phase 2)
Aortic Valve Stenosis (Phase 4)
Astrocytoma (Phase 1)
Carcinoma, Hepatocellular (Phase 2)
Cardiomyopathies (Phase 2)
Cardiovascular Diseases (Phase 3)
Cerebral Small Vessel Diseases (Phase 2)
Colorectal Neoplasms (Phase 2)
Connective Tissue Diseases (Phase 4)
COVID-19 (Phase 4)
Dementia, Vascular (Phase 2)
Depressive Disorder, Major (Phase 1/Phase 2)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Cardiomyopathies (Phase 4)
Dyspnea (Phase 2)
Eisenmenger Complex (Phase 2)
Emphysema (Phase 4)
Endothelial Cells (Phase 1)
Esophageal Neoplasms (Phase 2)
Fecal Incontinence (Phase 1)
Fertilization in Vitro (Phase 2/Phase 3)
Fontan Procedure (Phase 3)
Gastroparesis (Phase 4)
Glioblastoma (Phase 1)
Glucose Intolerance (Phase 3)
Head and Neck Neoplasms (Phase 2)
Healthy Volunteers (Phase 2)
Heart Defects, Congenital (Phase 3)
Heart Failure (Phase 3)
Heart Ventricles (Phase 1)
Hypertension (Phase 2)
Hypertension, Pulmonary (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Hypotension (Phase 4)
Insulin Resistance (Phase 3)
Ischemic Stroke (Phase 2)
Kidney Failure, Chronic (Phase 1/Phase 2)
Larynx (Early Phase 1)
Lip Diseases (Early Phase 1)
Liver Cirrhosis (Phase 4)
Liver Neoplasms (Phase 2)
Lower Urinary Tract Symptoms (Phase 4)
Lung Diseases, Interstitial (Phase 3)
Mouth Neoplasms (Phase 2)
Multiple Myeloma (Phase 2)
Muscular Dystrophies (Early Phase 1)
Muscular Dystrophy, Duchenne (Phase 4)
Nausea (Phase 4)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Nephrolithiasis (Phase 4)
Obesity (Phase 4)
Pain (Phase 4)
Pancreatic Neoplasms (Phase 2)
Parkinson Disease (Phase 4)
Prediabetic State (Phase 4)
Premature Ejaculation (Phase 4)
Priapism (Phase 2)
Prostate (Phase 2)
Prostatic Neoplasms (Phase 3)
Pulmonary Arterial Hypertension (Phase 4)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Quality of Life (Phase 4)
Raynaud Disease (Phase 3)
Respiratory Distress Syndrome (Phase 4)
Scleroderma, Systemic (Phase 4)
Sexual Dysfunction, Physiological (Phase 4)
Sexual Dysfunctions, Psychological (Phase 3)
Smoking (Phase 1)
Spinal Cord Injuries (Phase 4)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Stroke, Lacunar (Phase 2)
Ulcer (Phase 3)
Ureteral Diseases (Phase 4)
Urinary Bladder, Overactive (Phase 4)
Urinary Incontinence, Stress (Phase 1)
Urination Disorders (Phase 4)
Vomiting (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
